1. Home
  2. GCGR vs DMAC Comparison

GCGR vs DMAC Comparison

Compare GCGR & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GCGR

General Catalyst Global Resilience Merger Corp. Class A Ordinary Shares

N/A

Current Price

$10.00

Market Cap

461.9M

Sector

N/A

ML Signal

N/A

Logo DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

SELL

Current Price

$8.30

Market Cap

501.0M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
GCGR
DMAC
Founded
2026
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
461.9M
501.0M
IPO Year
2026
2018

Fundamental Metrics

Financial Performance
Metric
GCGR
DMAC
Price
$10.00
$8.30
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
★ $15.50
AVG Volume (30 Days)
110.2K
★ 190.7K
Earning Date
N/A
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $500,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.95
$5.25
52 Week High
$10.20
$11.00

Technical Indicators

Market Signals
Indicator
GCGR
DMAC
Relative Strength Index (RSI) 42.60 43.60
Support Level $9.96 $5.86
Resistance Level $10.12 $8.58
Average True Range (ATR) 0.03 0.81
MACD -0.00 -0.17
Stochastic Oscillator 33.33 6.23

Price Performance

Historical Comparison
GCGR
DMAC

About GCGR General Catalyst Global Resilience Merger Corp. Class A Ordinary Shares

General Catalyst Global Resilience Merger Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: